The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison

References

• Madan S, Kumar S. Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. Therapy. 2011;8(4):415–429.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2014. Bethesda, MD: National Cancer Institute; 2017.
   Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Voorhees PM, Hassoun H, et al. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014;7(1):97–111.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–2074.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Alsina M, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16(1):11–20.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Bringhen S, Richardson PG, et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 2014;99(6):1114–1122.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. JCO. 2009;27(36):6086–6093.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010;116(19):3743–3750.
   PubMed Web of Science ®Google Scholar
• Richardson P, Schlag R, Khuageva N, et al. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011;153(2):212–221.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. JCO. 2013;31(4):448–455.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. JCO. 2006;24(19):3113–3120.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895–903.
   PubMed Web of Science ®Google Scholar
• Corso A, Mangiacavalli S, Varettoni M, et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res. 2010;34(4):471–474.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934–941.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. JCO. 2010;28(34):5101–5109.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Wu E, Yu A, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–945.
   PubMed Web of Science ®Google Scholar
• Chan A, Cutter G, Fox RJ, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. J Comp Eff Res. 2017;6(4):313–323.
   PubMed Web of Science ®Google Scholar
• Odom D, Mladsi D, Purser M, et al. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer. 2017;2017:6121760.
   PubMedGoogle Scholar
• Pocoski J, Li N, Ayyagari R, et al. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. JBM. 2016;7:129–137.
   Google Scholar
• Strand V, Betts KA, Mittal M, et al. Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison. Rheumatol Ther. 2017;4(2):349–362.
   PubMed Web of Science ®Google Scholar
• Van Sanden S, Baculea S, Diels J, et al. Comparative efficacy of ibrutinib versus obinutuzumab + chlorambucil in first-line treatment of chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Adv Ther. 2017;34(7):1650–1661.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–4753.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. JCO. 2014;32(7):634–640.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martinez-Lopez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120(13):2581–2588.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Iida S, Ogawa G, et al. Randomized phase II study to optimize melphalan, prednisolone and bortezomib (mpb) in transplant-ineligible newly diagnosed multiple myeloma (ndmm): Japan Clinical Oncology Group Study (JCOG1105). Poster session presented at: 23rd Congress of the European Hematology Association (EHA); 2018 June 15; Stockholm, Sweden.
   Google Scholar
• San Miguel J, Blade J, Shpilberg O, et al. Randomized, open label, phase 2 study of siltuximab (an anti-IL-6 mAb) and bortezomib-melphalan-prednisone versus bortezomib-melphalan-prednisone in patients with newly diagnosed multiple myeloma. Blood. 2014;123(26):4136–4142.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Flinn IW, Rifkin R, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. JCO. 2015;33(33):3921–3929.
   PubMed Web of Science ®Google Scholar
• Facon T, Lee JH, Moreau P, et al. Phase 3 study (CLARION) of cartfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM). Clin Lymph Myel Leuk. 2017;17(Suppl 1):e26–e27.
   Google Scholar
• Dimopoulos MA, Mateos M-V, Cavo M, et al. One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): Alcyone. Presented at: American Society of Hematology Annual Meeting; 2018 December 1–4; San Diego, CA.
   Google Scholar
• Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115–1123.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Hashim M, He J, Hu P, et al. Is there a consensus regarding clinically relevant non-inferiority margins used for key oncology endpoints in non-inferiority oncology trials? Value Health. 2018;21:S228.
   Web of Science ®Google Scholar
• Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252–264.
   PubMed Web of Science ®Google Scholar
• Velcade® (bortezomib) [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc. 2019, https://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf, assessed at Oct 25, 2019
   Google Scholar
• Jimenez-Zepeda V, Reece DE, Arleigh MR, et al. Real-World outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant ineligible MM patients: a multi-institutional report from the National Myeloma Canada Research Network (MCRN) database. Blood. 2018;132(Suppl 1):2008–2008.
   Google Scholar
• Anjo J, Rider A, Gaudig M. PCN340 - real-world usage of bortezomib in combination with melphalan and prednisone (VMP) as Frontline (FL) treatment in Stem Cell Transplant (SCT) ineligible Multiple Myeloma (MM) patients across EU5 countries. Value Health. 2018;21:S72.
   Web of Science ®Google Scholar
• Mohty M, Terpos E, Mateos M-V, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymph Myel Leuk. 2018;18(10):e401–e419.
   PubMed Web of Science ®Google Scholar